FY26
| Code | Size | Price |
|---|
| TAR-T31899-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
FY26 is a potent Os(II) anticancer drug candidate, exerts its activity by generating reactive oxygen species and disrupting the redox balance in cancer cells Coadministration of FY26 and nontoxic doses of L-BSO allows the potentiation of its anticancer activity, and most remarkably, it improves the selectivity for cancer cells versus normal fibroblasts.
CAS:
1255143-82-8
Formula:
C23H28F6IN4OsP
Molecular Weight:
822.6
Purity:
0.98
SMILES:
CC1=CC=C(C(C)C)C=C1>>CN(C)C2=CC=C([N]3=NC4=CC=CC=[N]4[Os+]3I)C=C2.F[P-](F)(F)(F)(F)F
References
1. Fu Y.; Habtemariam A.; Pizarro A. M.; van Rijt S. H.; Healey D. J.; Cooper P.; Shnyder S. D.; Clarkson G. J.; Sadler P. J. Organometallic Osmium Arene Complexes with Potent Cancer Cell Cytotoxicity. J. Med. Chem. 2010, 53, 8192?8196.10.1021/jm100560f
2. Romero-Canel?n I, Mos M, Sadler PJ. Enhancement of Selectivity of an Organometallic Anticancer Agent by Redox Modulation. J Med Chem. 2015 Oct 8;58(19):7874-80. doi: 10.1021/acs.jmedchem.5b00655. Epub 2015 Sep 23. PubMed PMID: 26397305; PubMed Central PMCID: PMC4601049.